Communications
29 September 2021
Vol. 2 No. 1 (2021)

Comparing genomic profiles of tumour and peritumoral biopsies to find new possible biomarkers for glioblastoma therapy.

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
617
Views
192
Downloads

Authors

The study of glioblastoma genomic profiles permits the use of CNAs load to identify patients with poor prognosis and the understanding of the genomic signatures essential for the disease maintenance and the identification of new potential biomarkers.

Altmetrics

Downloads

Download data is not yet available.

Citations

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803-20.
2. Ricard D, Idbaih A, Ducray F, et al. Primary brain tumours in adults. Lancet 2012;379:1984-96.
3. Persano L, Rampazzo E, Della Puppa A, et al. The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implications. Sci World J 2011;11:1829-41.
4. Lemée JM, Clavreul A, Menei P. Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. Neuro Oncol 2015;17:1322-32.

How to Cite



Comparing genomic profiles of tumour and peritumoral biopsies to find new possible biomarkers for glioblastoma therapy. (2021). Biomedical Science and Engineering, 2(1). https://doi.org/10.4081/bse.170